What is happening?
Novo Nordisk announced the U.S. Food and Drug Administration (FDA) approval of Wegovy™ (semaglutide) for obesity on June 4, 2021.
Why is this important?
Key Takeaways and Next Steps
The coverage of weight-loss drugs is now under consideration by some plans due to the positive outcomes Wegovy has achieved in clinical trials. Plans hope weight loss will result in improved health outcomes.
The decision to cover (or not cover) weight-loss drugs belongs with each payer or plan sponsor based on what is best for their patient population.
For those who choose to cover Wegovy, PSG recommends the following:
The scope of utilization could feel daunting to plan sponsors with one in three Americans currently struggling with obesity. PSG’s analytics team identified the number of members diagnosed with obesity and the representation (percentage) of the overall membership (for integrated clients).
Not a PSG client? Engage our clinical team to: